Could fewer injections control wet AMD? new study tests faricimab's staying power
NCT ID NCT06890026
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 742 people newly diagnosed with wet age-related macular degeneration (nAMD) who received 3 monthly injections of faricimab (Vabysmo) instead of the usual 4. The goal was to see how long the effect lasted before another injection was needed. Researchers tracked how many weeks passed after the third injection until the next treatment, aiming to reduce the burden of frequent eye injections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Faricimab (Vabysmo) injection
What this could lead to
If successful, this could show that 3 loading doses of faricimab are enough to control nAMD, potentially reducing the number of injections patients need.
What could go wrong
This is a completed observational study, not a controlled trial, so results may not apply to all patients. The shorter loading regimen might not work as well as the recommended 4 doses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Ophthalmology, Rigshospitalet
Glostrup Municipality, 2600, Denmark